论文部分内容阅读
甲状腺相关性眼病(thyroid-associated ophthalmopathy，TAO)是一种器官特异性自身免疫性疾病，其伴随的一系列症状对患者的躯体健康及心理健康造成了难以评估的危害，严重影响患者生活质量。但目前尚缺乏公认的特效治疗方法，即便在有效治疗后TAO所致容貌改变亦难以完全恢复。因此，避免或消除与TAO发生和发展相关的危险因素至关重要。高胆固醇血症作为TAO发生和发展的潜在危险因素之一，逐渐受到临床研究者的关注。近期研究发现，他汀类药物可显著降低Graves病患者眼病的发病率与眼病发展的风险。基于TAO的炎症病理学机制，他汀类药物有可能成为预防及延缓TAO发生和发展的新希望。“,”Thyroid-associated ophthalmopathy(TAO)is an organ-specific autoimmune disease. A series of symptoms related to it cause serious harm to the physical and mental health of patients, and then seriously affect their quality of life. However, there is stilly lack of specific treatment methods at present. Even after effective treatment, it is difficult to fully recover the appearance changes. Therefore, it is very important to avoid or reduce the risk factors associated with the occurrence and progress of TAO. Hypercholesterolemia, as one of the potential risk factors for the occurrence and progression of TAO, has been concerned by more clinical researchers. Recent studies have found that statins can significantly reduce the incidence of ophthalmopathy and the risk of ophthalmopathy progression in patients with Graves disease. Based on the inflammatory pathological mechanism of TAO, statins may become a new hope to prevent and delay the occurrence and progression of TAO.